|
|
Directeur :
INSERM U545
Institut Pasteur
de Lille
Université de Lille 2
Rattachée à l'IFR 114
|
| Maladies cardiovasculaires, métaboliques et neurodégénératives |
PPARs. Apolipoprotéines. LDL. Athérosclérose. Syndrome métabolique |
|
Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, Blanc-Brude O, Barateau V, Potteaux S, Merva R, Esposito B, Teissier E, Daemen MJ, Leseche G, Boulanger C, Tedgui A, Mallat Z.
Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice.
Circulation, 2007, 115:2168-2177. |
Balmforth AJ, Grant PJ, Scott EM, Wheatcroft SB, Kearney MT, Staels B, Marx N.
Inter-subject differences in constitutive expression levels of the clock gene in man.
Diab Vasc Dis Res, 2007, 40:39-43. |
Barter P, Gotto AM, Larosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC for the Treating to New Targets Investigators.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
N Engl J Med, 2007, 357:1301-1310. |
Blanc-Brude OP, Teissier E, Castier Y, Leseche G, Bijnens AP, Daemen M, Staels B, Malla Z, Tedgui A.
IAP survivin regulates atherosclerotic macrophage survival.
Arterioscler Thromb Vasc Biol, 2007, 27:901-907. |
Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G.
PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.
Cell Metab, 2007, 6:137-143. |
Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Torpier G, Fruchart JC, Staels B, Duriez P,
Lacroix D.
The PPARα activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
J Cardiovasc Pharmacol 2007, 49: 408-415. |
Cappello C, Saugel B, Huth KC, Zwergal A, Krautkramer M, Furman C, Rouis M, Wieser B, Schneider HW, Neumeier D, Brand K.
Ozonized low density lipoprotein (ozLDL) inhibits NF-kappaB and IRAK-1-associated signaling.
Arterioscler Thromb Vasc Biol, 2007, 27:226-232. |
Cariou B, Staels B.
FXR : a promising target for the metabolic syndrome ?
Trends Pharmacol Sci, 2007, 28:236-243. |
Cousein E, Barthelemy C, Poullain S, Simon N, Lestavel S, Williame V, Joiris E, Danel C, Clavey V, Brossard D, Robert H, Crauste-Manciet S, Vaccher C, Odou P.
P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7
model and an in vivo model.
Prog Neuropsychopharmacol Biol Psychiatry, 2007, 4:878-886. |
Drouineaud V, Sagot P, Garrido C, Logette E, Deckert V, Gambert P, Jimenez C, Staels B, Lagrost L, Masson D.
Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists.
Mol Hum Reprod, 2007, 13:373-379. |
Duriez P, Bordet R, Berthelot P.
The strange case of Dr HDL and Mr HDL : Does a NOís story illuminate the mystery of HDLís dark side uncovered by Dr HDLís drug targeting CETP ?
Med Hypotheses, 2007, 69:752-757. |
Evans A, Marques-Vidal P, Ducimetiere P, Montaye M, Arveiler D, Bingham A, Ruidavets JB, Amouyel P, Haas B, Yarnell J, Ferrieres J, Fumeron F, Luc G, Kee F, Cambien F.
Patterns of alcohol consumption and cardiovascular risk in Northern Ireland and France.
Ann Epidemiol, 2007, 17:S75-S80. |
Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH.
IP receptor-dependent activation of PPARγ by stable prostacyclin analogues.
Biochem Biophys Res Commun, 2007, 360:821-827. |
Fievet C, Fruchart JC, Staels B.
Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of
PPAR agonists in the treatment of cardiometabolic disorders.
Front Biosc, 2007, 12:4132-4156. |
Flajollet S, Lefebvre B, Cudejko C, Staels B, Lefebvre P.
The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor.
Mol Cell Endocrinol, 2007, 270:23-32. |
Fruchart JC.
Is lipoprotein(a) a clinically meaningful risk marker for cardiovascular events in healthy women ?
Nat Clin Pract Cardiovasc Med, 2007,4:242-243. |
Fontaine C, Rigamonti E, Nohara A, Gervois O, Teissier E, Fruchart JC, Staels B, Chinetti-Gbaguidi G.
Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages.
Circ Res, 2007, 101:40-49. |
Fontaine C, Staels B.
The orphan nuclear receptor Reverba : a transcriptional link between circadian rhythmicity and cardiometabolic disease.
Curr Opin Lipidol, 2007, 18:141-146. |
Gallou-Kabani C, Vige A, Gross MS, Boileau C, Rabes JP, Fruchart-Najib J, Jais JP, Junien C.
Resistance to high-fat diet in the female progeny of obese mice fed a control diet during the periconceptual, gestation and lactation periods.
Am J Physiol Endocrinol Metab, 2007, 292:E1095-E1100. |
Gervois P, Fruchart JC, Staels B.
Drug insight : mechanisms of action and therapeutic applications for agonists of PPAR.
Nat Clin Pract Endocrinol Metab, 2007, 3:145-156. |
Hondares E, Pineda-Torra I, Iglesias R, Staels B, Villarroya F, Giralt M.
PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle.
Biochem Biophys Res Commun, 2007, 354:1021-1027. |
Jquirim-Souissi I, Jelassi A, Addad F, Hassine M, Najah M, Hamda KB, Maatouk F, Farha MB, Bouslema A,
Rouis M, Slimane MN.
Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Am J Cardiol, 2007, 100:23-27. |
Kahri J, Fruchart-Najib J, Matikainen N, Fruchart JC, Vakkilainen J, Taskinen MR.
The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes : no relationship between apo A-V and postheparin plasma lipolytic activity.
Diabetes Care, 2007, 30:2083-2085. |
Kuipers K, Stroeve JHM, Caron S, Staels B.
Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Curr Opin Lipidol, 2007, 18:289-297. |
Mekhloufi J, Vitrac H, Yous S, Duriez P, Jore D, Gardes-Albert M, Bonnefont-Rousselot D.
Quantification of the water/lipid affinity of melatonin and a pinoline derivative in lipid models.
J Pineal Res, 2007, 42:330-337. |
Nakamach T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zhao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D.
PPARα agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Diabetes, 2007, 56:1662-1670. |
Nicaud V, Francomme C, Ruidavets JB, Luc G, Arveiler D, Kee F, Evans A, Morrison C, Blankenberg S, Cambien F, Tiret L.
Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction.
J Mol Med, 2007, 85:771-775. |
Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome.
Clin Chem Lab Med, 2007, 45:1133-1139. |
Paumelle R, Staels B.
PPAR mediate pleiotropic actions of statins.
Circ Res, 2007, 100:1394-1395. |
Perez-Mendez O, Alvarez-Salcedo P, Carreon Torres E, Luc G, Arce Fonseca M, De La Pena A, Cruz Robles D, Garcia JJ, Vargas-Alarcon G.
Palmitic acid in HDL is associated to low apo A-I fractional catabolic rates in vivo.
Clin Chim Acta, 2007, 378:53-58. |
Raichur S, Lau P, Staels B, Muscat GE.
Retinoid-related orphan receptor gamma regulates several genes that control metabolism in skeletal muscle cells : links to modulation of reactive oxygen species production.
J Mol Endocrinol, 2007, 39:29-44. |
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B.
Safety issues and prospects for future generations of PPAR modulators.
Biochim Biophys Acta, 2007, 1771:1065-1081. |
Sharma AM, Staels B.
PPARγ and adipose tissue ñ Understanding obesity-related changes in regulation of lipid and glucose metabolism.
J Clin Endocrinol Metab, 2007, 92:386-395. |
Staels B, Kuipers F.
Bile acid sequestrants and the treatment of type 2 diabetes mellitus.
Drugs, 2007, 67:1383-1392. |
Tailleux A, Staels B.
Atheroprotective effect of the rexinoid bexarotene in a murine model. Atheroorg Commentaries, International Atherosclerosis Society
Website, June 2007. |
Larigauderie G, Jay M, Rouis M
Towards the elucidation of the role of perilipin in human macrophages.
Atherosclerosis, 2007, 190:16-17. |
Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC.
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor a agonists.
Bioorg Med Chem Lett, 2007, 17:4689-4693. |
| |
Blanc-Delmas E, Lebegue N, Wallez V, Leclerc V, Yous S, Carato P, Farce A, Bennejean C, Renard P, Caignard DH, Audinot-Bouchez V, Chomarat P, Boutin J, Hennuyer N, Louche K, Carmona MC, Staels B, Penicaud L, Casteilla L, Lonchampt M, Dacquet C, Chavatte P, Berthelot P, Lesieur D.
Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists.
Bioorg Med Chem, 2006, 14:7377-7391. |
Boadu E, Choi HY, Lee DWK, Waddington EI, Chan T, Asztalos B, Vance JE, Chan A, Castro G, Francis GA.
Correction of apolipoprotein A-I mediated lipid efflux and high density lipoprotein particle formation in human Niemann-Pick type C disease fibroblasts.
J Biol Chem, 2006, 281:37081-90. |
Bordet R, Gele P, Duriez P, Fruchart JC.
PPARs : a new target for neuroprotection (Editorial).
J Neurol Neurosurg Psychiatry, 2006, 77:285-287. |
Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M.
PPAR : a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.
Biochem Soc Trans, 2006, 34:1341-1346. |
Boukhtouche F, Vodjdani G, Jarvis CI, Bakouche J, Staels B, Mallet J, Mariani J, Lemaigre-Dubreuil Y, Brugg B.
Human retinoic acid receptor-related orphan receptor alpha1 overexpression protects neurones against oxidative stress-induced apoptosis.
J Neurochem, 2006, 96:1778-1789. |
Boulanger E, Moranne O, Wautier MP, Witko-Sarsat V, Descamps-Latscha B, Kandoussi A, Grossin N, Wautier JL.
Changes in glycation and oxidation markers in patients starting peritoneal dialysis : a pilot study.
Perit Dial Int, 2006, 26:207-212. |
Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR.
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.
J Clin Invest, 2006, 116:1052-1062. |
Cariou B, Staels B.
The expanding role of the bile acid receptor FXR in the small intestine.
J Hepatol, 2006, 44:1213-1215. |
Cariou B, Van Harmelen K, Duran-Sandoval D, Van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G,
Fruchart JC, Gonzalez FJ, Kuipers F, Staels B.
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.
J Biol Chem, 2006, 281:11039-11049. |
Caron S, Cariou B, Staels B.
FXR : more than a bile acid receptor ?
Endocrinology, 2006, 147:4022-4024. |
Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V,
Scharfmann VR, Staels B, Fruhbeck G, Froguel P.
Transcription factor TCF7L2 genetic study in the French population. Expression in human‚ βcells and adipose tissue and strong association with type 2 diabetes.
Diabetes, 2006, 55:2903-2908. |
Chinetti G, Fruchart JC, Staels B.
Transcriptional regulation of macrophage cholesterol trafficking by PPARα and LXR.
Biochem Soc Trans, 2006, 34:1128-1131. |
Chinetti G, Staels B.
Inflammation et maladies métaboliques et vasculaires : approches pharmacologiques.
In : Journ. Annu. Diabetol. Hotel Dieu, Flammarion Médecine-Sciences, 2006, pp 153-158. |
Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B, Krempf M.
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c.
J Biol Chem, 2006, 281:6211-6218. |
Cuaz-Perolin C, Jguirim I, Larigauderie G, Jlassi A, Furman C, Moreau M, Chapman MJ, Fruchart JC, Slimane MN, Mezdour H, Rouis M.
Apolipoprotein E knockout mice overexpressing human tissue inhibitor of metalloproteinase 1 are protected
against aneurysm formation but not against atherosclerotic plaque development.
J Vasc Res, 2006, 43:493-501. |
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJP, Larosa JC, Schachner H, Shepherd J, Waters DD. For The Treating To New Targets Investigators.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome : analysis of the Treating to New Targets study.
The Lancet, 2006, 368:919-928. |
Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, Staels B, Lestavel S.
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.
Biochem Biophys Res Commun, 2006, 340:1259-1263. |
Ekambome Bassene C, Suzenet F, Hennuyer N, Staels B, Caignard DH, Dacquet C, Renard P, Guillaumet G.
Studies towards the conception of new selective PPARβ/δ ligands.
Bioorg Med Chem Lett, 2006, 16:45284532. |
Fievet C, Fruchart JC, Staels B.
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Curr Opin Pharmacol, 2006, 6:606-614. |
Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P.
PPAR in reproductive tissues : from gametogenesis to parturition.
J Endocrinol, 2006, 189:199-209. |
Fruchart JC, Duriez P.
Fibrate.
In : “Dyslipoproteinämien und Atherosklerose: Diagnostik, Therapie und Prävention”, Eds. P. Schwandt, K.G. Parhofer, Schattauer, Stuttgart, 2006, pp 761-780. |
Fruchart JC, Duriez P.
Mode of action of fibrates in the regulation of triglyceride and HDL cholesterol metabolism.
Drugs of Today, 2006, 42:39-64. |
Germain P, Staels B, Dacquet C, Spedding M, Laudet V.
Overview of nomenclature of nuclear receptors.
Pharmacol Rev, 2006, 58:685-704. |
Gilde AJ, Fruchart JC, Staels B.
PPARs at the crossroads of obesity, diabetes, and cardiovascular disease.
J Am Coll Cardiol, 2006, 48(9):A24-A32. |
Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B.
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
Mol Cell Biol, 2006, 20:7632-7644. |
Gizard F, Staels B.
Rôle protecteur de la voie fibrates/p16INK4A dans les lésions vasculaires occlusives.
Med Sci, 2006, 22:351-353. |
Helleboid-Chapman A, Helleboid S, Jakel H, Timmerman C, Sergheraert C, Pattou F, Fruchart-Najib J, Fruchart JC.
Glucose regulates LXR• subcellular localization and function in rat pancreatic •-cells.
Cell Res, 2006, 16:661-670. |
Jakel H, Fruchart-Najib J, Fruchart JC.
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis.
Drug News Perspect, 2006, 19:91-97. |
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC.
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins ?
Annals of Medicine, 2006, 38:2-10. |
Joyce CW, Wagner EM, Basso F, Amar MJ, Freeman LA, Shamburek RD, Knapper CL, Syed J, Wu J, Vaisman BL, Fruchart-Najib J, Billings EM, Paigen B, Remaley A., Santamarina-Fojo S, Brewer HB.
ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis.
J Biol Chem, 2006, 281:33053-33065. |
Lalloyer F, Fievet C, Lestavel S, Torpier G, Van Der Veen J, Touche V, Bultel S,Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A.
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Arterioscler Thromb Vasc Biol, 2006, 26:2731-2737. |
Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B.
PPARα improves pancreatic adaptation to insulin-resistance in obese mice and reduces lipotoxicity in human islets.
Diabetes, 2006, 55:1605-1613. |
Larigauderie G, Bouhlel MA, Furman C, Jaye M, Fruchart JC, Rouis M.
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages.
Atherosclerosis, 2006, 189:142-148. |
Larigauderie G, Cuaz-Perolin C, Ben Younes A, Furman C, Lasselin C, Copin C, Jaye M, Fruchart JC, Rouis M.
Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β-oxidation.
FEBS Journal, 2006, 273:3498-3510. |
Lefebvre P, Chinetti G, Fruchart JC, Staels B.
Sorting out the roles of PPARα in energy metabolism and vascular homeostasis.
J Clin Invest, 2006, 116:571-580. |
Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P On Behalf Of The Prime Study Group.
Plasma cystatin-C and development of coronary heart disease : the PRIME Study.
Atherosclerosis, 2006, 185:375-380. |
Luc G, Duriez P, J.C. Fruchart JC.
Triglycerides and risk for atherosclerotic disease.
In : “Comprehensive Management of High Risk Cardiovascular Patients”, Eds A.M. Gotto, P.P. Toth, Informa Healthcare Inc, USA, 2006, pp 341-388. |
Majali KA, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ.
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.
Diabetologia, 2006, 49:527-537. |
Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, Sunder-Plassmann L, Bach H, Haug C, Bachem M, Stojakovic T, Marz W, Hombach V, Koenig, W, Staels B, Marx N.
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients. Data from a randomized placebo-controlled trial.
Arterioscler Thromb Vasc Biol, 2006, 26:845-850. |
Mezdour H, Larigauderie G, Castro G, Torpier G, Fruchart J, Nowak M, Fruchart JC, Rouis M, Maeda N.
Characterization of a new mouse model for human apolipoprotein A-I/C III/A-IV deficiency.
J Lipid Res, 2006, 47:912-920. |
Michalik L, Auwerx J, Berger JP, Chatterjee K, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’rahilly S, Palmer CNA, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International union of
pharmacology.
LXI. Peroxisome proliferators activated receptors.
Pharmacol Res, 2006, 58:726-741. |
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM : Asteroid Investigators.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID Trial.
JAMA, 2006, 295:1556-1565. |
Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B.
Acute antiinflammatory properties of statins involve PPARα via inhibition of the protein kinase C signaling pathway.
Circ Res, 2006, 98:361-369. |
Perez-Mendez O, Duhal N, Lacroix B, Bonte JP, Fruchart JC, Luc G.
Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
Clin Chim Acta, 2006, 368:149-154. |
Post SM, Groenendijk M, Van Der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HMG, Staels B, Rensen PCN.
Cholesterol 7α-hydroxylase deficiency in mice on an apoE 3-Leiden background increases hepatic ABCA1 mRNA expression and HDLcholesterol.
Arterioscler Thromb Vasc Biol, 2006, 26:2724-2730. |
Pourcet B, Fruchart JC, Staels B, Glineur C.
Selective PPAR modulators, dual and pan PPAR agonists : multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
Expert Opin Emerg Drugs, 2006, 11:379-401. |
Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, Larosa J, Grundy S, Waters D For The Treating To New Targets Investigators.
Effect of lowering low density lipoprotein cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes : the Treating to New Targets (TNT) Study.
Diabetes Care, 2006, 29:1220-1226. |
Shiri-Sverdlov R, Wouters K, Van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, Van Bilsen M, Hofker MH.
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
J Hepatol, 2006, 44:732-741. |
Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, Van Berkel TJC, Parks JS, Staels B, Rothblat GH, Fievet C, Hayden MR.
Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma
highdensity lipoprotein cholesterol levels in vivo.
Circulation, 2006, 114:1301-1309. |
Sparatore A, Godio C, Perrino E, Romeo S, Staels B, Fruchart JC, Crestani M.
[4-(2H-1,2,3-benzotriazol-2-yl) phenoxy] alkanoic acids as agonists of PPARs.
Chem Biodiversity, 2006, 3:385-395. |
Staels B.
Metformin and pioglitazone : effectively treating insulin resistance.
Curr Med Res Opin, 2006, 22(2):27-37. |
Staels B.
When the Clock stops ticking, metabolic syndrome explodes.
Nat Med, 2006, 12:54-55. |
Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA, Belanger J, Kaeding J, Staels B, Caron P, Tukey RH, Barbier O.
The liver X-recepor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice.
Hepatology, 2006, 44:368-378. |
Verwaerde C, Delanoye A, Macia L, Tailleux A, Wolowczuk I.
Influence of high-fat feeding on both naïve and antigen-experienced T-cell immune response in DO10.11 mice.
Scand J Immunol, 2006, 64:457-66. |
Waters DD, La Rosa JC, Barter P, Fruchart JC, Gotto AM, Carter R, Breazna A, Kastelein JJP, Grundy SM.
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study.
J Am Coll Cardiol, 2006, 48:1793-1799. |
Zamble A, Carpentier M, Kandoussi A, Sahpaz S, Petrault O, Ouk T, Hennuyer N, Fruchart JC, Bordet R, Duriez P, Bailleul F, Martin-Nizard F.
Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms.
J Cardiovasc Pharmacol, 2006, 47: 599-608. |
Zamble A, Yao D, Martin-Nizard F, Sahpaz S, Offoumou M, Bordet R, Duriez P, Brunet C, Bailleul F.
Vasoactivity and antioxidant properties of Microdesmis keayana roots.
J Ethnopharmacology, 2006, 104:263-269. |
Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B.
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPARα activators : Clinical and experimental evidence.
Arterioscler Thromb Vasc Biol, 2006, 26:977-986.
|
| |
Annelise GENOUX
Directeur de thèse : Jean-Charles Fruchart
« Régulation différentielle de la transcription des gènes humain et murin de l’apolipoprotéine A5 en réponse aux cytokines pro-inflammatoires par différents mécanismes impliquant respectivement NF-kB ou COUP-TFI. Régulation transcriptionnelle du gène de l’apo A5 par RORa »
Université de Lille 2
Le 09/02/2006 |
Coralie FONTAINE
Directeur de thèse : Bart Staels
« Rôle et régulation du récepteur nucléaire orphelin rev-Erb »
Université de Lille 2
Le 23/06/2006 |
Stéphanie BULTEL-BRIENNE
Directeur de thèse : Véronique Clavey
« Régulation de la captation sélective des esters de cholestérol dans différents types cellulaires : implication d’un réseau complexe de protéines (Sr-B1, apolipoprotéine E, lipoprotéine lipase…) »
Université de Lille 2
Le 11/10/2006 |
Romain ROBILLARD
Directeur de thèse : Bart Staels
« Rôle du facteur de transcription TreP-132 dans la prolifération et la différenciation des cellules de cancers mammaires »
Université de Lille 2
Le 16/10/2006 |
Fanny LALLOYER
Directeur de thèse : Catherine Fiévet
« Facteurs de risque de l’athérosclérose : modulation et régulation par les récepteurs nucléaires PPARalpha et RXR »
Université de Lille 2
Le 30/10/2006 |
Clarisse CUAZ-PEROLIN
Directeur de thèse : Mustapha Rouis
« Les macrophages et l’athérosclérose : identification et étude de certains gènes impliqués dans la formation des cellules spumeuses, l’inflammation artérielle et la rupture des plaques d’athérome. Effet protecteur de l’acide Boswellique »
Université de Lille 2
Le 19/12/2006 |
| |
Philippe GERVOIS
Université de Lille 2
Le 7 avril 2006 |
|
|
